logo

Eyenovia, Inc. (EYEN)



Trade EYEN now with
  Date
  Headline
8/12/2019 4:10:51 PM Eyenovia Q2 Loss/share $0.44 Vs. Loss $0.33 Year Ago
7/11/2019 9:08:29 AM Eyenovia Prices Public Offering Of 4.39 Mln Shares At $2.78 Per Share
7/10/2019 4:20:39 PM Eyenovia Announces Proposed Public Offering Of Common Stock
6/4/2019 8:39:49 AM Eyenovia Enrolls First Patient In Phase III CHAPERONE Study For Progressive Myopia
5/14/2019 6:39:50 AM Eyenovia Q1 Net Loss $5.9 Mln Or $0.50/Shr Vs Loss $3.4 Mln Or $0.45/Shr Last Year
3/27/2019 6:44:18 AM Eyenovia Q4 Net Loss $6.2 Mln Or $0.60/Shr Vs Loss $2.2 Mln Or $0.84/Shr Last Year
2/6/2019 8:35:21 AM Eyenovia Says FDA Accepted IND Application To Initiate CHAPERONE Study
12/19/2018 9:08:32 AM Eyenovia Prices Underwritten Public Offering Of 1.20 Mln Shares At $2.45/shr
12/3/2018 9:32:07 AM Eyenovia Completes Patient Enrollment In MicroStat MIST-1 Study And Enrolls First Patient In MIST-2 Study
11/26/2018 9:08:56 AM Eyenovia Begins Phase III MicroStat Program For Pharmacologic Mydriasis: Enrolls First Patient In MIST-1 Study
11/13/2018 7:36:20 AM Eyenovia Says FDA Accepted IND Application To Initiate Phase III Trials Of MicroStat For Diagnostic Mydriasis
11/13/2018 6:47:30 AM Eyenovia Q3 Net Loss $4.3 Mln Or $0.43/Shr Vs Loss $0.9 Mln Or $0.10/Shr Last Year
8/14/2018 6:33:35 AM Eyenovia Q2 Net Loss $3.3 Mln Or $0.33 Per Share
8/13/2018 8:33:42 AM Eyenovia Announces Positive Results Of Its EYN PG21 Proof-of-concept Study Of Microdose Latanoprost
  
 
>